What are the DAWN criteria (age, NIH Stroke Scale score, and infarct core volume thresholds) for mechanical thrombectomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

DAWN Criteria for Mechanical Thrombectomy

The DAWN criteria use age-adjusted clinical-imaging mismatch to select patients for thrombectomy 6-24 hours after last known well, matching specific NIHSS scores with maximum infarct core volumes based on age thresholds of ≤80 versus >80 years 1, 2.

Specific DAWN Eligibility Criteria

The DAWN trial established three distinct patient groups based on clinical-imaging mismatch 3, 2:

Group A: Age ≥80 years

  • NIHSS ≥10
  • Infarct core 0-20 cm³

Group B: Age <80 years with moderate deficit

  • NIHSS 10-20
  • Infarct core 0-30 cm³

Group C: Age <80 years with severe deficit

  • NIHSS ≥21
  • Infarct core 31-50 cm³

Additional Required Criteria

Beyond the age-NIHSS-core mismatch, patients must have:

  • Large vessel occlusion of intracranial internal carotid artery or proximal middle cerebral artery (M1) confirmed on CTA or MRA 3, 2
  • Time window: 6-24 hours from last known well 1
  • Imaging modality: Core volume measured by CT perfusion or DW-MRI using automated software (RAPID was used in the trial) 3

Critical Implementation Points

The 2018 AHA/ASA Guidelines explicitly state that DAWN or DEFUSE-3 eligibility criteria should be strictly adhered to in clinical practice 1. This is a Class I, Level A recommendation for the 6-16 hour window and Class IIa, Level B-R for the 16-24 hour window 1.

Why Strict Adherence Matters

The guidelines emphasize that DAWN and DEFUSE-3 are the only randomized controlled trials demonstrating benefit beyond 6 hours 1. The DAWN trial showed remarkable outcomes with 49% achieving functional independence (mRS 0-2) versus 13% in controls, with an adjusted difference of 33 percentage points 1, 2.

Common Pitfalls to Avoid

  • Do not extrapolate beyond these criteria: While observational data suggests some trial-ineligible patients may benefit 4, the guidelines mandate strict adherence to proven criteria
  • Core volume is absolute: A patient age 75 with NIHSS 18 and 35 cm³ core does NOT qualify (exceeds the 30 cm³ limit for that NIHSS range)
  • Age cutoff is binary: The 80-year threshold creates distinct eligibility groups with different core volume limits
  • Imaging is mandatory: Clinical assessment alone is insufficient; you must have CT perfusion or DW-MRI to measure core volume 1

Practical Algorithm

  1. Confirm time window: 6-24 hours from last known well
  2. Obtain vascular imaging: Confirm ICA or M1 occlusion
  3. Measure infarct core: Use automated software on CTP or DW-MRI
  4. Apply age-based criteria:
    • If age ≥80: Requires NIHSS ≥10 AND core ≤20 cm³
    • If age <80 with NIHSS 10-20: Core must be ≤30 cm³
    • If age <80 with NIHSS ≥21: Core must be 31-50 cm³
  5. Proceed to thrombectomy if all criteria met

The DAWN criteria demonstrated 90-day mortality of 19% with thrombectomy versus 18% with medical management, with symptomatic ICH rates of 6% versus 3% (not statistically different) 2, establishing both efficacy and safety in this carefully selected population.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.